Excessive Daytime SleepinessPhase 3HAROSA IVNCT02978651
Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness
A Phase 3 study testing Pitolisant (BF2.649) in people with Excessive Daytime Sleepiness and Obstructive Sleep Apnea, run by Bioprojet at 2 sites in France.
Trial summary
The first objective of this study is to demonstrate the efficacy and safety of pitolisant given at 10, 20, or 40 mg per day versus placebo during 12 weeks of the Double Blind period, to treat the Excessive Daytime Sleepiness (EDS) in patients with Obstructive Sleep Apnea (OSA) refusing the nasal Continuous Positive… Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Excessive Daytime Sleepiness, Obstructive Sleep Apnea
- What is being tested?
- Pitolisant (BF2.649)
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 0 participants
- Where
- 2 sitesFrance
- Study dates
- Start not givento Jan 2017
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male and/or female outpatients aged from at least 18 years.
- Patients complaining of EDS refusing to be treated by nCPAP therapy or having been submitted to nCPAP therapy for a minimum period of 3 months, and still complaining of EDS despite the efforts made beforehand to obtain an efficient nCPAP therapy.
- Polysomnography performed (for patients submitted to nCPAP therapy - under nCPAP) between V1 and V2 or during the last 12 months with Apnea-Hypopnea Index (AHI): for patients without nCPAP therapy ≥ 15; for patients under nCPAP therapy less or equal to 10.
- For patients submitted to nCPAP therapy: nCPAP ≥ 4 hours / day (compliance checked on the clock-time counter of the CPAP machine)
- Mini Mental State Examination (MMSE) ≥ 28
- Beck Depression Inventory - 13 items (BDI-13) score < 16 and item G (suicidal ideation) of BDI-13 = 0
Show all 11Show fewer
- Body Mass Index (BMI) less or equal to 40 kg/m²
- Epworth Sleepiness Scale (ESS) ≥ 12
- Female patients with child-bearing potential using a medically accepted method of birth control (i.e. oral contraceptives of normal average dosage) agreeing to continue this method throughout the study, and during the month following treatment discontinuation, being negative to serum pregnancy test performed at the screening visit.
- If specified by the investigator, the patient must be willing not to operate a car (if sleepy at wheel) or heavy machinery for the duration of the trial or as long as the investigator deems it clinically indicated. In addition, the patient should be willing to maintain during the study their usual behaviors which could affect their diurnal sleepiness (e.g. circadian rhythm, caffeine consumption, nocturnal sleep duration)
- Patients having signed and dated the informed consent form.
Who cannot join
- Patients suffering from chronic severe insomnia in accordance with the International Classification of Sleep Disorders (ICSD 2005) without OSA
- Patients with co-existing narcolepsy (ICSD 2005), judged on clinical criteria
- Patients with sleep debt not due to OSA (according to the physician' s judgment)
- Patients with non-respiratory sleep fragmentation (restless leg syndrome…)
- Shift work, professional drivers
- Refusal from the patient to stop any current therapy for EDS or predictable risk for the patient to stop the therapy
Show all 20Show fewer
- Patients suffering from a psychiatric disease
- Acute or chronic disease preventing the improvement assessment, e.g. severe chronic obstructive pulmonary disease (COPD)
- Current or recent (within one year) history of drug, alcohol, narcotic or other substance abuse or dependence
- Any significant serious abnormality of the cardiovascular system, e.g. recent myocardial infarction, angina, hypertension or dysrhythmias (within the previous 6 months), Electrocardiogram Fridericia corrected QT interval higher than 450 ms, history of left ventricular hypertrophy or mitral valve prolapse
- Severe co-morbid medical or biological conditions that may jeopardize study participation at the discretion of the investigator (particularly in the cardiovascular system and the instable diabetes).
- Positive serology tests (HIV, HCV and HBsAg)
- Pregnant or breast-feeding women.
- Women with child-bearing potential and no efficient birth-control method
- Patients unable to understand the study protocol.
- Patients with suspected or known hypersensitivity to study medication
- Patients with a dominant arm deficiency impeding the achievement of the tests
- Patients using a prohibited medication.
- Congenital galactose poisoning, glucose and galactose malabsorption, deficit in lactase.
- Patients participating in another study or being in a follow-up period for another study.
Trial locations and contacts
2 sites in 1 country.
France2 sites
Laboratoire du sommeil Clinique de Physiologie, Sommeil et Exercice Pôle Thorax et Vaisseaux CHU de Grenoble
Grenoble, 38043
Hôpital Gui de Chauliac, CHU Montpellier, Unité des Troubles du Sommeil et de l'Eveil
Montpellier, 34295
About this study
Official title: Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness
The first objective of this study is to demonstrate the efficacy and safety of pitolisant given at 10, 20, or 40 mg per day versus placebo during 12 weeks of the Double Blind period, to treat the Excessive Daytime Sleepiness (EDS) in patients with Obstructive Sleep Apnea (OSA) refusing the nasal Continuous Positive Airway Pressure (nCPAP) therapy or treated by nCPAP but still complaining of EDS.
The secondary objectives of the study include assessing the long-term tolerance as well as the maintenance of efficacy of pitolisant given at 10, 20 or 40 mg per day during 39 weeks of Open Label Extension period.
- Being tested
- Pitolisant (BF2.649), Placebo Oral Tablet
- Keywords
- EDS, OSA
- Medical subject headings
- Disorders of Excessive Somnolence, Sleep Apnea, Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pitolisant (BF2.649)Drug
Placebo Oral TabletDrug
| Study group | Role | What they receive |
|---|---|---|
| Pitolisant (BF2.649) | Experimental | Histamine H3 receptor H3R antagonist/ inverse agonist Receives: Drug: Pitolisant (BF2.649) |
| Placebo | Placebo comparator | Placebo Receives: Drug: Placebo Oral Tablet |
What is being measured
The primary outcome is the main question the study is designed to answer.
Epworth sleepiness scale (ESS)
Measured: Change from Baseline of ESS at 12 weeks and Change from Baseline of ESS at 52 weeks
Secondary outcomes (9)
Percentage of ESS responders
Measured: at week 12 /52 versus baseline
Reduction of sleepiness and sleep episodes on the sleep diary
Measured: at week 12 /52 versus baseline
Improvement in vigilance according to Oxford Sleep Resistance (OSleR) test
Measured: at week 12 /52 versus baseline
European Quality of Life Questionnaire (EQ-5D)
Measured: at week 12 /52 versus baseline
Leeds Sleep Evaluation Questionnaire (LSEQ)
Measured: at week 12 /52 versus baseline
The Pichot Fatigue Scale
Measured: at week 12 /52 versus baseline
Trail Making Test parts (A and B)
Measured: at week 12 /52 versus baseline
Improvement in Clinical Global Impression (CGI)
Measured: at week 12 /52 versus baseline
Z-score: composite score including ESS and OSLER results
Measured: at week 12 /52 versus baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Dec 2016 (estimated)
- Primary completionJan 2017
Why it stopped: Strategic decision of Sponsor
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Excessive Daytime SleepinessStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Bioprojet
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02978651
- Sponsor's protocol ID
- P16 04/ / BF2.649
- Other IDs
- 2016-002963-32, 2016
- Acronym
- HAROSA IV
- Status last verified
- Nov 2016
- First submitted
- 29 Nov 2016
- Last updated
- 24 Nov 2017
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Nov 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness
- ClinicalTrials.gov ID
- NCT02978651
- Acronym / sponsor ID
- HAROSA IV / P16 04/ / BF2.649
- Keywords
- EDS, OSA
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Strategic decision of Sponsor
- Enrolment
- 0 participants (actual)
- Lead sponsor
- BioprojetUniversity, hospital or other
- Primary completion
- Jan 2017 (actual)
- First posted
- 1 Dec 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The first objective of this study is to demonstrate the efficacy and safety of pitolisant given at 10, 20, or 40 mg per day versus placebo during 12 weeks of the Double Blind period, to treat the Excessive Daytime Sleepiness (EDS) in patients with Obstructive Sleep Apnea (OSA) refusing the nasal Continuous Positive Airway Pressure (nCPAP) therapy or treated by nCPAP but still complaining of EDS.
The secondary objectives of the study include assessing the long-term tolerance as well as the maintenance of efficacy of pitolisant given at 10, 20 or 40 mg per day during 39 weeks of Open Label Extension period.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Pitolisant (BF2.649) | Experimental | Drug: Pitolisant (BF2.649)Histamine H3 receptor H3R antagonist/ inverse agonist |
| Placebo | Placebo comparator | Drug: Placebo Oral TabletPlacebo |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Male and/or female outpatients aged from at least 18 years.
- Patients complaining of EDS refusing to be treated by nCPAP therapy or having been submitted to nCPAP therapy for a minimum period of 3 months, and still complaining of EDS despite the efforts made beforehand to obtain an efficient nCPAP therapy.
- Polysomnography performed (for patients submitted to nCPAP therapy - under nCPAP) between V1 and V2 or during the last 12 months with Apnea-Hypopnea Index (AHI): for patients without nCPAP therapy ≥ 15; for patients under nCPAP therapy less or equal to 10.
- For patients submitted to nCPAP therapy: nCPAP ≥ 4 hours / day (compliance checked on the clock-time counter of the CPAP machine)
- Mini Mental State Examination (MMSE) ≥ 28
Key exclusion criteria (20 listed)
- Patients suffering from chronic severe insomnia in accordance with the International Classification of Sleep Disorders (ICSD 2005) without OSA
- Patients with co-existing narcolepsy (ICSD 2005), judged on clinical criteria
- Patients with sleep debt not due to OSA (according to the physician' s judgment)
- Patients with non-respiratory sleep fragmentation (restless leg syndrome…)
- Shift work, professional drivers
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pitolisant (BF2.649) | Drug | Pitolisant (BF2.649) |
| Placebo Oral Tablet | Drug | Placebo |
Primary outcome
Epworth sleepiness scale (ESS)
Time frame: Change from Baseline of ESS at 12 weeks and Change from Baseline of ESS at 52 weeks
9 secondary outcomes
Percentage of ESS responders
Time frame: at week 12 /52 versus baseline
Reduction of sleepiness and sleep episodes on the sleep diary
Time frame: at week 12 /52 versus baseline
Improvement in vigilance according to Oxford Sleep Resistance (OSleR) test
Time frame: at week 12 /52 versus baseline
European Quality of Life Questionnaire (EQ-5D)
Time frame: at week 12 /52 versus baseline
Leeds Sleep Evaluation Questionnaire (LSEQ)
Time frame: at week 12 /52 versus baseline
The Pichot Fatigue Scale
Time frame: at week 12 /52 versus baseline
Trail Making Test parts (A and B)
Time frame: at week 12 /52 versus baseline
Improvement in Clinical Global Impression (CGI)
Time frame: at week 12 /52 versus baseline
Z-score: composite score including ESS and OSLER results
Time frame: at week 12 /52 versus baseline
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Nov 2017.
- Individual participant dataSharing planned: No
Related trials for Excessive Daytime Sleepiness
RecruitingPhase 3
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)
Apnea, Sleep Disorders
RecruitingPhase 2/3
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
Narcolepsy Type 1, Narcolepsy Type 2
RecruitingPhase 2
A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder
Major Depressive Disorder (MDD)
RecruitingPhase 3
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
RecruitingPhase 2/3
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Narcolepsy Type 1, Narcolepsy Type 2
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Pitolisant (BF2.649) in people with Excessive Daytime Sleepiness and Obstructive Sleep Apnea, run by Bioprojet at 2 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 24 Nov 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Epworth sleepiness scale (ESS) (time frame: Change from Baseline of ESS at 12 weeks and Change from Baseline of ESS at 52 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Nov 2017.